The company has received the final approval from the United States Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Deferasirox tablets in the strength of 180 mg, Alembic Pharmaceuticals said in a BSE filing.from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3e9BJSU
via IFTTT
0 comments:
Post a Comment